GCP
SYRE icon

GSA Capital Partners’s Spyre Therapeutics SYRE Stock Holding History

GSA Capital Partners’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-450
Closed -$89K – 1789
2021
Q3 		$89K Buy
+450
New +$78.7K 0.01% 1332
2021
Q1 		– Sell
-1,953
Closed -$384K – 1483
2020
Q4 		$384K Sell
1,953
-243
-11% -$50.4K 0.06% 598
2020
Q3 		$389K Buy
+2,196
New +$406K 0.06% 561

Other funds holding SYRE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

GSA Capital Partners's SYRE Position: Q4 2021 in Review

GSA Capital Partners sold out of Spyre Therapeutics (SYRE) in Q4 2021, closing a stake of 450 shares — an estimated $89K sold.

GSA Capital Partners first reported a position in SYRE in Q3 2020 and held it in 3 quarters. The position peaked at $389K in Q3 2020. 85 funds tracked by Wall St. Rank hold SYRE as of Q4 2021.

  • GSA Capital Partners reported no remaining Spyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • GSA Capital Partners sold 450 Spyre Therapeutics shares in Q4 2021, an estimated $89K.
  • GSA Capital Partners first reported a position in Spyre Therapeutics in Q3 2020 and held it in 3 quarters.
  • GSA Capital Partners's Spyre Therapeutics position peaked at $389K in Q3 2020.
  • 85 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2021.

Based on GSA Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.